This report covers the US and Germany and provides an Excel-based forecast model for the Fragile X Syndrome market through 2030.
The FXS market in the US and Germany for 2025 is valued at $28.7 million. The market is projected to grow at a compound annual growth rate (CAGR) of 14.7% between 2020 and 2030, reaching $111.9 million by 2030.
The introduction of two pipeline agents is a major driver of growth of the FXS market. In order of entry, these products will be Harmony Biosciences’ Zygel and Shionogi’s zatolmilast. The sales of high-priced pipeline agents Zygel and zatolmilast represent the most impactful drivers of growth.
The FXS market in the US and Germany for 2025 is valued at $28.7 million. The market is projected to grow at a compound annual growth rate (CAGR) of 14.7% between 2020 and 2030, reaching $111.9 million by 2030.
The introduction of two pipeline agents is a major driver of growth of the FXS market. In order of entry, these products will be Harmony Biosciences’ Zygel and Shionogi’s zatolmilast. The sales of high-priced pipeline agents Zygel and zatolmilast represent the most impactful drivers of growth.
Scope
- Overview of Fragile X Sundrome (FXS), including epidemiology, symptoms, diagnosis, and disease management.
- Annualized FXS therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2020 to 2030.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the FXS market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for FXS. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the US and German FXS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the US and German FXS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the FXS therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1. Preface
3. Disease Overview
4. Epidemiology
5. Current Treatment Options
6. Unmet Needs and Opportunities
7. R&D Strategies
8. Pipeline Assessment
9. Market Outlook
10. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- GSK plc
- Eli Lilly and Co
- Otsuka Pharmaceutical Co Ltd
- Shionogi Inc
- Viatris
- Sanofi
- Takeda (Pty) Ltd
- Boehringer Ingelheim
- Johnson and Johnson, Inc.
- Janssen
- Harmony Biosciences Holdings Inc
